Introducing Cheiron: The First Pharmacy-Specific AI Platform in South Korea
A groundbreaking AI startup backed by the SK Group has unveiled a revolutionary platform tailored specifically for the pharmaceutical industry in South Korea. Known as Cheiron, this cutting-edge search platform is the brainchild of PhynX Lab, a Silicon Valley-based venture under SK Networks, designed to cater to professionals in the pharmaceutical sector, including researchers and pharmacists.
How Cheiron Works
Cheiron boasts key features such as one-stop and semantic-based search capabilities. Powered by a modular RAG framework – an advanced iteration of RAG (Retrieval-Augmented Generation) – the platform can retrieve pertinent information from diverse databases to generate precise responses. Leveraging natural language processing, self-verification mechanisms, and quick answer generation, Cheiron can pinpoint specific data based on intent with unparalleled accuracy.
PhynX Lab elucidated, “Modular RAG’s expandability to new technologies or data enables rapid, high-quality answer generation through seamless module connections. Its versatile structure allows for independent or interconnected operation, akin to Lego blocks, enhancing flexibility. Additionally, the framework optimizes data storage selection, bolstering security measures.”
Cheiron adeptly extracts data from various academic search platforms like PubMed, general search engines, open sources, and internal corporate documents. This singular platform can tap into multiple databases, streamlining information retrieval processes. Moreover, it facilitates workflow automation, data organization, document creation, and supports major languages beyond Korean.
Significance of Cheiron
PhynX Lab developed Cheiron to overcome the limitations of existing healthcare LLMs. Conventional models are constrained by rigid structures reliant on pre-learned data, leading to data misinterpretation and unfounded responses based on unlearned data. During demonstrations, the startup reported significant reductions in document search times with Cheiron, potentially enhancing research planning stages by up to 80% compared to conventional methods.
Beyond search result provision, Cheiron can facilitate research, candidate substance discovery, clinical trial design, production and process development, and market analysis. The AI startup aims to extend its flagship solution to pharmaceutical entities, with plans to further enhance the platform’s capabilities.
The Larger Industry Trend
In a trend towards AI-powered drug discovery platforms, Daewoong Pharmaceutical recently introduced its genAI-driven platform based on an extensive compound database. Other pharmacy-specific genAI solutions, like Google’s Tx-LLM and IBM’s collaboration with Boehringer Ingelheim, highlight the industry’s shift towards leveraging AI models for new drug development and disease cell identification.
